Validation of a biomarker tool capable of measuring the absorbed dose soon after exposure to ionizing radiation.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
14 04 2021
Historique:
received: 25 04 2020
accepted: 19 03 2021
entrez: 15 4 2021
pubmed: 16 4 2021
medline: 10 11 2021
Statut: epublish

Résumé

A radiological or nuclear attack could involve such a large number of subjects as to overwhelm the emergency facilities in charge. Resources should therefore be focused on those subjects needing immediate medical attention and care. In such a scenario, for the triage management by first responders, it is necessary to count on efficient biological dosimetry tools capable of early detection of the absorbed dose. At present the validated assays for measuring the absorbed dose are dicentric chromosomes and micronuclei counts, which require more than 2-3 days to obtain results. To overcome this limitation the NATO SPS Programme funded an Italian-Egyptian collaborative project aimed at validating a fast, accurate and feasible tool for assessing the absorbed dose early after radiation exposure. Biomarkers as complete blood cell counts, DNA breaks and radio-inducible proteins were investigated on blood samples collected before and 3 h after the first fraction of radiotherapy in patients treated in specific target areas with doses/fraction of about: 2, 3.5 or > 5 Gy and compared with the reference micronuclei count. Based on univariate and multivariate multiple linear regression correlation, our results identify five early biomarkers potentially useful for detecting the extent of the absorbed dose 3 h after the exposure.

Identifiants

pubmed: 33854097
doi: 10.1038/s41598-021-87173-3
pii: 10.1038/s41598-021-87173-3
pmc: PMC8047015
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8118

Références

Radiat Prot Dosimetry. 2020 Jul 24;189(4):428-435
pubmed: 32391564
Radiat Res. 2016 Nov;186(5):423-435
pubmed: 27710702
Radiat Res. 2010 Feb;173(2):245-53
pubmed: 20095857
Health Phys. 2015 Jul;109(1):54-68
pubmed: 26011498
Nucleic Acids Res. 2009 Jul;37(12):3912-23
pubmed: 19401436
Radiother Oncol. 2013 Sep;108(3):362-9
pubmed: 23849169
Int J Radiat Biol. 2017 Jan;93(1):75-80
pubmed: 27559844
J Innate Immun. 2019;11(1):74-85
pubmed: 30296787
Mil Med. 2001 Dec;166(12 Suppl):85-7
pubmed: 11778449
Ann Ist Super Sanita. 2009;45(3):278-86
pubmed: 19861733
Health Phys. 2005 Nov;89(5):505-12
pubmed: 16217194
Health Phys. 2013 Oct;105(4):351-5
pubmed: 23982611
Ann Ist Super Sanita. 2009;45(3):265-71
pubmed: 19861731
Mutagenesis. 2010 Mar;25(2):109-11
pubmed: 20064897
Radiat Environ Biophys. 2008 Feb;47(1):63-9
pubmed: 18087709
Health Phys. 2001 Oct;81(4):446-9
pubmed: 11569639
Health Phys. 2012 Dec;103(6):787-801
pubmed: 23111526
J Innate Immun. 2013;5(4):304-14
pubmed: 23571274
Oncotarget. 2017 Jun 28;8(52):90496-90500
pubmed: 29163848
Radiat Prot Dosimetry. 2019 Dec 31;186(1):15-23
pubmed: 31330012
Med Phys. 2003 Aug;30(8):2065-71
pubmed: 12945972
PLoS One. 2018 Feb 23;13(2):e0193412
pubmed: 29474504
Acta radiol. 1954 Jan;41(1):21-9
pubmed: 13138291
Int J Radiat Biol. 2020 Jan;96(1):22-34
pubmed: 30605362
Radiat Prot Dosimetry. 2014 Jun;159(1-4):61-76
pubmed: 24925901
Int J Radiat Biol. 2008 Mar;84(3):227-35
pubmed: 18300023
Mutagenesis. 2011 May;26(3):393-9
pubmed: 21227901
Curr Opin Hematol. 2017 Nov;24(6):496-501
pubmed: 28985193
Health Phys. 2018 Dec;115(6):727-742
pubmed: 30299338
Int J Mol Sci. 2019 Oct 26;20(21):
pubmed: 31717816
Health Phys. 2010 Nov;99 Suppl 5:S171-83
pubmed: 20938227
Mutagenesis. 2011 Jan;26(1):11-7
pubmed: 21164177
Stem Cells. 1995 May;13 Suppl 1:69-77
pubmed: 7488970
Int J Radiat Biol. 2014 Oct;90(10):909-13
pubmed: 24827851
Int J Radiat Biol. 2017 Jan;93(1):36-47
pubmed: 27673504
Front Oncol. 2012 Jun 04;2:58
pubmed: 22675673
Dose Response. 2019 Dec 12;17(4):1559325819894794
pubmed: 31853238
Health Phys. 2010 Nov;99 Suppl 5:S184-91
pubmed: 20938228

Auteurs

Anna Giovanetti (A)

Division of Health Protection Technologies, ENEA-Italian National Agency for New Technologies, Energy and Sustainable Economic Development, 00123, Rome, Italy. anna.giovanetti@enea.it.

Raffaella Marconi (R)

Scientific Direction, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, 00149, Rome, Italy.

Noha Awad (N)

Epidemiology Department, High Institute of Public Health, Alexandria University, Alexandria, 21561, Egypt.

Hala Abuzied (H)

Alexandria University Cancer Research Cluster, Alexandria, 21561, Egypt.

Neveen Agamy (N)

Nutrition Department, High Institute of Public Health, Alexandria University, Alexandria, 21561, Egypt.

Mohamed Barakat (M)

Alexandria University Cancer Research Cluster, Alexandria, 21561, Egypt.

Cecilia Bartoleschi (C)

Division of Health Protection Technologies, ENEA-Italian National Agency for New Technologies, Energy and Sustainable Economic Development, 00123, Rome, Italy.

Gianluca Bossi (G)

Oncogenomic and Epigenetic Unit, Department of Diagnostic Research and Technological Innovation, IRCCS - Regina Elena National Cancer Institute, 00144, Rome, Italy.

Marco Canfora (M)

Clinical Trial Center, Biostatistics and Bioinformatics, IRCCS Regina Elena National Cancer Institute, 00144, Rome, Italy.

Amr A Elsaid (AA)

Oncology Department, Faculty of Medicine, Alexandria University, Alexandria, 21561, Egypt.

Laura Ioannilli (L)

Department of Biology, University of Rome "Tor Vergata", 00133, Rome, Italy.

Horeya M Ismail (HM)

Alexandria University Cancer Research Cluster, Alexandria, 21561, Egypt.

Yasmine Amr Issa (YA)

Medical Biochemistry Department, Faculty of Medicine, University of Alexandria, Alexandria, 21561, Egypt.

Flavia Novelli (F)

Division of Health Protection Technologies, ENEA-Italian National Agency for New Technologies, Energy and Sustainable Economic Development, 00123, Rome, Italy.

Maria Chiara Pardini (MC)

Division of Health Protection Technologies, ENEA-Italian National Agency for New Technologies, Energy and Sustainable Economic Development, 00123, Rome, Italy.

Claudio Pioli (C)

Division of Health Protection Technologies, ENEA-Italian National Agency for New Technologies, Energy and Sustainable Economic Development, 00123, Rome, Italy.

Paola Pinnarò (P)

Departments of Radiation Oncology, IRCCS - Regina Elena National Cancer Institute, 00144, Rome, Italy.

Giuseppe Sanguineti (G)

Departments of Radiation Oncology, IRCCS - Regina Elena National Cancer Institute, 00144, Rome, Italy.

Mohamed M Tahoun (MM)

Epidemiology Department, High Institute of Public Health, Alexandria University, Alexandria, 21561, Egypt.

Riccardo Turchi (R)

Department of Biology, University of Rome "Tor Vergata", 00133, Rome, Italy.

Lidia Strigari (L)

IRCCS Azienda Ospedaliera Universitaria di Bologna, 40138, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH